Delivery Order SPE2DB24D1205-SPE2DB25FDADP
- Not listed
- The Defense Logistics Agency awarded a $17,422.25 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in treating inflammatory conditions. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 4, 2025, and performance occurring at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order is issued under a larger Indefinite Delivery Contract...
- The Defense Logistics Agency has awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a brand-name pharmaceutical product used in the treatment of autoimmune conditions. This competitively awarded, firm fixed-price delivery order was executed on August 27, 2025, with an ultimate completion date of August 28, 2025. The contract will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $41,926.99 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls pharmaceutical supply. This non-competitive delivery order, awarded on August 13, 2025, with an ultimate completion date of August 14, 2025, represents a child contract under AmerisourceBergen's larger federal pharmaceutical supply vehicle. The product will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $1,510.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL pharmaceutical supplies on September 3, 2025, with completion targeted for September 4, 2025. This non-competitive delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $5,506.33 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price contract, which is set to be completed by August 21, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The delivery will be performed at the contractor's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 22, 2025, with an ultimate completion date of August 25, 2025. This is a firm fixed-price, non-set-aside contract with performance at the awardee's Conshohocken, Pennsylvania location. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL with a ceiling value of $1,185.69. This is a firm fixed price delivery order under a non-set-aside competitive procurement. The contract is set to be completed by August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $33,781.22 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in treating autoimmune conditions. The contract is a firm fixed-price delivery order with no set-aside designation, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of HUMIRA(CF) Pen 40 mg/0.4 mls, a pharmaceutical product used for treating autoimmune conditions. This firm fixed-price delivery order, valued at $1,132.95, represents a non-set-aside competitive award with an ultimate completion date of September 4, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a $5,303.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FDADPDelivery Order
The Defense Logistics Agency awarded a $53,154.52 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This competitively awarded, firm fixed-price delivery order is set to be completed by September 5, 2025, with fulfillment services provided from the contractor's location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 prime vendor agreement running through December 2026 that enables comprehensive pharmaceutical and medical supply support to military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a substantial federal contract portfolio with the Defense Logistics Agency focused on supplying brand-name and generic medications, vaccines, and specialized medical devices across multiple therapeutic categories. The company's status as a competitively awarded prime vendor reflects its established capability to meet federal procurement standards and support the medical supply chain requirements of the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $53.2k | 9/4/25 |